Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis
Abstract
Discontinuation of bDMARDs leads to an increased risk of losing remission or LDA and radiographic progression, while tapering doses of bDMARDs does not increase the risk of relapse (LDA) or radiographic progression, even though there is an increased risk of losing remission.
Keywords
systematic review
meta-analysis
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
treatment outcome
female
male
Withholding Treatment*
risk factors
radiography
antirheumatic agents / therapeutic use*
arthritis
rheumatoid / drug therapy*
disease progression
pmid:29187350
doi:10.1136/annrheumdis-2017-212423
sophie henaux
adeline ruyssen-witrand
arnaud constantin
rheumatoid / diagnostic imaging
biological products / therapeutic use*
maintenance chemotherapy
Access
Citation
ID:
113002
References
Blockchain Verification
Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
113002
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
Creates 1,000,000 NFT tokens for this article
Token Features:
- ERC-1155 Standard NFT
- 1 Million Supply per Article
- Transferable via MetaMask
- Permanent Blockchain Record
Scan with Saymatik Web3.0 Wallet